SEC Tracker
Get the app

uniQure QURE

uniQure announces Q3 2026 financial results and updates

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. FDA granted priority review for AMT-130 with PDUFA target action date of May 1, 2027
  2. Cash and investments of $768.4 million as of September 30, 2026 expected to fund operations into 2030
  3. Confirmatory study design aligned with FDA, U.S. patient screening to begin by end of 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when uniQure files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  2. Pacira BioSciences PCRX public float $758M, Jun 30, 2025
  3. Cogent Biosciences COGT public float $773M, Jun 30, 2025
  4. Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
  5. Immunome IMNM public float $729M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.